1. Part 2

2. Faculty/Presenter Disclosure Faculty/Presenter:[insert name here] Relationships with commercial interests: Grants/research support:[insert company/organization name(s) here] Speaker’s bureau/honoraria:[insert company/organization name(s) here] Consulting fees:[insert company/organization name(s) here] Other:[insert company/organization name(s) here]

3. Disclosure of Commercial Support This program has received financial support from AstraZeneca Canada Inc. in the form of an educational grant This program has received in-kind support from AstraZeneca Canada Inc. in the form of logistical support Potential for conflict(s) of interest: [Faculty/speaker name] has received [payment/funding] from [organization supporting the program AND/OR organization whose product(s) are being discussed in this program] AstraZeneca Canada Inc. markets or benefits from the sale of a product(s) that will be discussed in this program: exenatide (Byetta), saxagliptin (Onglyza)

4. Mitigating Potential Bias Potential sources of bias identified in the preceding 2 slides have been mitigated as follows: Information presented is evidence-based Recommendations made are evidence- or guidelines-based rather than personal recommendations of the presenter Material has been reviewed by an Educational Committee responsible for overseeing the program’s Needs Assessment and subsequent content development